IN2013MU03309A - - Google Patents

Info

Publication number
IN2013MU03309A
IN2013MU03309A IN3309MU2013A IN2013MU03309A IN 2013MU03309 A IN2013MU03309 A IN 2013MU03309A IN 3309MU2013 A IN3309MU2013 A IN 3309MU2013A IN 2013MU03309 A IN2013MU03309 A IN 2013MU03309A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
acceptable derivative
cefepime
stereoisomer
compound
Prior art date
Application number
Other languages
English (en)
Inventor
Sachin Bhagwat
Mahesh Vithalbhai Patel
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HUE14806074A priority Critical patent/HUE057504T2/hu
Priority to MX2016005161A priority patent/MX2016005161A/es
Priority to CN201480069915.6A priority patent/CN106102741A/zh
Priority to EP14806074.2A priority patent/EP3060213B1/en
Priority to PCT/IB2014/065522 priority patent/WO2015059643A1/en
Priority to KR1020167013330A priority patent/KR102340010B1/ko
Priority to CN202110966872.3A priority patent/CN113577084A/zh
Priority to BR112016008979-0A priority patent/BR112016008979B1/pt
Priority to RU2016115376A priority patent/RU2702361C2/ru
Priority to JP2016525054A priority patent/JP2016538258A/ja
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to DK14806074.2T priority patent/DK3060213T3/da
Priority to PL14806074T priority patent/PL3060213T3/pl
Priority to PT148060742T priority patent/PT3060213T/pt
Priority to AU2014338612A priority patent/AU2014338612C1/en
Priority to ES14806074T priority patent/ES2902456T3/es
Priority to NZ719215A priority patent/NZ719215A/en
Priority to IN3309MU2013 priority patent/IN2013MU03309A/en
Priority to CA2928364A priority patent/CA2928364C/en
Priority to US15/030,526 priority patent/US9827235B2/en
Publication of IN2013MU03309A publication Critical patent/IN2013MU03309A/en
Priority to JP2019083866A priority patent/JP6886996B2/ja

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IN3309MU2013 2013-10-22 2014-10-22 IN2013MU03309A (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
DK14806074.2T DK3060213T3 (da) 2013-10-22 2014-10-22 Farmaceutiske sammensætninger omfattende antibakterielle midler
MX2016005161A MX2016005161A (es) 2013-10-22 2014-10-22 Composiciones farmaceuticas que comprenden agentes antibacterianos.
EP14806074.2A EP3060213B1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
PCT/IB2014/065522 WO2015059643A1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
KR1020167013330A KR102340010B1 (ko) 2013-10-22 2014-10-22 항균제를 포함하는 제약학적 조성물
CN202110966872.3A CN113577084A (zh) 2013-10-22 2014-10-22 包含抗菌剂的药物组合物
BR112016008979-0A BR112016008979B1 (pt) 2013-10-22 2014-10-22 Composições farmacêuticas compreendendo agentes antibacterianos e seus usos
PL14806074T PL3060213T3 (pl) 2013-10-22 2014-10-22 Kompozycje farmaceutyczne zawierające środki antybakteryjne
JP2016525054A JP2016538258A (ja) 2013-10-22 2014-10-22 抗菌剤を含む医薬組成物
HUE14806074A HUE057504T2 (hu) 2013-10-22 2014-10-22 Antibakteriális szereket tartalmazó gyógyszerkészítmények
CN201480069915.6A CN106102741A (zh) 2013-10-22 2014-10-22 包含抗菌剂的药物组合物
RU2016115376A RU2702361C2 (ru) 2013-10-22 2014-10-22 Фармацевтические композиции, содержащие антибактериальные агенты
PT148060742T PT3060213T (pt) 2013-10-22 2014-10-22 Composições farmacêuticas compreendendo agentes antibacterianos
AU2014338612A AU2014338612C1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
ES14806074T ES2902456T3 (es) 2013-10-22 2014-10-22 Composiciones farmacéuticas que comprenden agentes antibacterianos
NZ719215A NZ719215A (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
IN3309MU2013 IN2013MU03309A (es) 2013-10-22 2014-10-22
CA2928364A CA2928364C (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
US15/030,526 US9827235B2 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
JP2019083866A JP6886996B2 (ja) 2013-10-22 2019-04-25 抗菌剤を含む医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3309MU2013 IN2013MU03309A (es) 2013-10-22 2014-10-22

Publications (1)

Publication Number Publication Date
IN2013MU03309A true IN2013MU03309A (es) 2015-07-17

Family

ID=52003012

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3309MU2013 IN2013MU03309A (es) 2013-10-22 2014-10-22

Country Status (18)

Country Link
US (1) US9827235B2 (es)
EP (1) EP3060213B1 (es)
JP (2) JP2016538258A (es)
KR (1) KR102340010B1 (es)
CN (2) CN106102741A (es)
AU (1) AU2014338612C1 (es)
BR (1) BR112016008979B1 (es)
CA (1) CA2928364C (es)
DK (1) DK3060213T3 (es)
ES (1) ES2902456T3 (es)
HU (1) HUE057504T2 (es)
IN (1) IN2013MU03309A (es)
MX (1) MX2016005161A (es)
NZ (1) NZ719215A (es)
PL (1) PL3060213T3 (es)
PT (1) PT3060213T (es)
RU (1) RU2702361C2 (es)
WO (1) WO2015059643A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014080A (es) * 2015-05-07 2018-07-06 Mutabilis Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
US20200316083A1 (en) * 2016-06-17 2020-10-08 Wockhardt Limited Antibacterial compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465428B1 (en) * 1999-08-27 2002-10-15 Aventis Pharma S.A. Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
UA91205C2 (ru) * 2004-12-17 2010-07-12 Венус Ремедиз Лимитед Антибиотическая комбинация амикацина и цефепима для создания общего раствора для лечения инфекций
RU2366450C1 (ru) * 2008-08-04 2009-09-10 Валентина Васильевна Малиновская Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций
WO2013014496A1 (en) * 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
AU2013268415B2 (en) * 2012-05-30 2017-05-25 Meiji Seika Pharma Co., Ltd. Novel beta-lactamase inhibitor and method for producing same
CN104884092A (zh) * 2013-01-14 2015-09-02 沃克哈特有限公司 用于治疗细菌感染的组合物和方法

Also Published As

Publication number Publication date
WO2015059643A1 (en) 2015-04-30
RU2016115376A (ru) 2017-11-28
PL3060213T3 (pl) 2022-02-14
BR112016008979A2 (es) 2017-08-01
RU2702361C2 (ru) 2019-10-08
US9827235B2 (en) 2017-11-28
AU2014338612C1 (en) 2020-09-24
KR20160072254A (ko) 2016-06-22
CA2928364C (en) 2021-11-23
DK3060213T3 (da) 2022-01-03
PT3060213T (pt) 2021-12-24
JP2016538258A (ja) 2016-12-08
EP3060213A1 (en) 2016-08-31
CN106102741A (zh) 2016-11-09
MX2016005161A (es) 2016-10-05
CN113577084A (zh) 2021-11-02
RU2016115376A3 (es) 2018-07-02
EP3060213B1 (en) 2021-10-13
CA2928364A1 (en) 2015-04-30
US20160303104A1 (en) 2016-10-20
AU2014338612B2 (en) 2019-12-19
HUE057504T2 (hu) 2022-05-28
BR112016008979B1 (pt) 2023-04-25
ES2902456T3 (es) 2022-03-28
JP2019116508A (ja) 2019-07-18
NZ719215A (en) 2020-04-24
KR102340010B1 (ko) 2021-12-16
JP6886996B2 (ja) 2021-06-16

Similar Documents

Publication Publication Date Title
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
IN2014MN02598A (es)
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
EP3082817A4 (en) Compositions for drug administration
MX2016006815A (es) Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam).
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MY181641A (en) Amino pyran ring derivative and composition and use thereof
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
EP3003360A4 (en) High potency pancreatin pharmaceutical compositions
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
IN2013MU03309A (es)
IN2013MU03704A (es)
IN2013MU03422A (es)
IN2013MU03308A (es)
IN2013MU03421A (es)
IN2014MU00859A (es)
EP3244930A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING POH DERIVATIVES
IN2013MU03565A (es)
MX2017010992A (es) Composiciones farmaceuticas estables que comprenden agente antibacteriano.